VSTM Stock Overview
A development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Verastem, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.97 |
| 52 Week High | US$13.82 |
| 52 Week Low | US$2.10 |
| Beta | 0.28 |
| 1 Month Change | 12.01% |
| 3 Month Change | 56.28% |
| 1 Year Change | -52.05% |
| 3 Year Change | -60.20% |
| 5 Year Change | -77.18% |
| Change since IPO | -95.51% |
Recent News & Updates
Recent updates
Verastem: Narrowed Market And Less Compelling Efficacy Warrant Rating Downgrade
May 26Verastem: Moving Forward
Sep 13Health Check: How Prudently Does Verastem (NASDAQ:VSTM) Use Debt?
Sep 01
Verastem Non-GAAP EPS of -$0.11 in-line
Aug 08Verastem: Looking Increasingly Attractive
Jun 29Verastem: Time To Take My Position Out Of Mothball
Apr 19Vectoring In On Verastem
Jan 12Shareholder Returns
| VSTM | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.1% | 0.4% | 1.5% |
| 1Y | -52.0% | -2.7% | 22.4% |
Return vs Industry: VSTM underperformed the US Biotechs industry which returned -2.7% over the past year.
Return vs Market: VSTM underperformed the US Market which returned 22.4% over the past year.
Price Volatility
| VSTM volatility | |
|---|---|
| VSTM Average Weekly Movement | 17.9% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 18.0% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: VSTM's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: VSTM's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 73 | Dan Paterson | www.verastem.com |
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205.
Verastem, Inc. Fundamentals Summary
| VSTM fundamental statistics | |
|---|---|
| Market cap | US$274.16m |
| Earnings (TTM) | -US$93.45m |
| Revenue (TTM) | US$10.00m |
27.4x
P/S Ratio-2.9x
P/E RatioIs VSTM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VSTM income statement (TTM) | |
|---|---|
| Revenue | US$10.00m |
| Cost of Revenue | US$0 |
| Gross Profit | US$10.00m |
| Other Expenses | US$103.45m |
| Earnings | -US$93.45m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.03 |
| Gross Margin | 100.00% |
| Net Profit Margin | -934.54% |
| Debt/Equity Ratio | 126.2% |
How did VSTM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/16 09:45 |
| End of Day Share Price | 2025/02/14 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Verastem, Inc. is covered by 25 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| Matthew Cross | Alliance Global Partners |
| Kalpit Patel | B. Riley Securities, Inc. |